AIDS International Training & Research Program (AITRP) Research Workshop Abuja, Nigeria Rockview Hotel Royale (Ameachi Hall) May 6, 2010 FINAL Agenda Sponsored.

Slides:

Advertisements

Similar presentations

Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.

Advertisements

TE/OR Subcommittee Presented to the Emergency Plan for AIDS Relief Scientific Steering Committee October 19, 2004.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.

Workshop on ART in Pregnancy, Breastfeeding, and Beyond Adult Treatment and PMTCT/Pediatric Technical Workgroups US Office of the Global AIDS Coordinator.

Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.

The Laboratory’s Key Role in Scale-Up and Sustainability Seema Meloni, Ph.D., M.P.H. Harvard School of Public Health AIDS 2012: Turning the Tide Together.

6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.

Leading By Example in the Public Health Approach to Antiretroviral Therapy Operations Research Agenda: Innovation & Collaboration What Can Industry Bring.

U. S. Senate Briefing World TB Day Celine Gounder, MD, ScM Center for TB Research, Johns Hopkins University Director for Delivery, CREATE On behalf of.

COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU.

Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,

ART drug resistance mutations Implications for TDF use Phyllis Kanki and Beth Chaplin Harvard PEPFAR Harvard School of Public Health.

Biomedical Engineering Program Opening Session Rob Murphy, MD Professor of Medicine and Biomedical Engineering Director, Center for Global Health Northwestern.

National TB/ Leprosy Programme Manager

Programs for HIV Prevention and TreatmentIRD UMI 174 Pediatric HIV Clinical Pharmacology Program Development in Thailand Tim R. Cressey Research Associate,

HIV Care and Treatment: Benefits of Electronic Medical Records Phyllis Kanki 1, Seema Meloni 1,Beth Chaplin 1, Bolanle Banigbe 2, Prosper Okonkwo 2 1 Harvard.

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

At What Cost? U.S. Leadership in Global Health in an Era of Austerity Dr. J. Stephen Morrison Senior Vice President; Director, Global Health Policy Center.

Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.

Afri-Can Synchronicity Forum Laico Lake Victoria Hotel Entebbe, Uganda 17 _ 19 Jan 2013 OVERVIEW: Creating A Common Platform for HIV Vaccine Research and.

Global Response to HIV/AIDS Nigerian Nurses Association of USA June 30, 2006 Carolyn M Hall, MSN/MPH, ACRN Global HIV/AIDS Program U.S. Department of Health.

Antiretroviral Drug Resistance Basic Knowledge Global Impact Utility of Global Surveillance Anthony Amoroso, MD Assistant Professor of Medicine University.

HIV/AIDS: A Global and Regional Perspective AIDS in Post 2015 Development Agenda.

Downloaded from Accelerate scaling up of TB/HIV activities in Tanzania Dr. N.G.SIMKOKO WHO/NTLP - Tanzania.

Central Asia Regional Health Security Workshop George C. Marshall European Center for Security Studies April 2012, Garmisch-Partenkirchen, Germany.

Antiretroviral therapy, cancer prevention and care in Africa The experience of the IeDEA West Africa Collaboration Pr Francois Dabis and Dr Antoine Jaquet.

TUBERCULOSIS IN THE AGE OF HIV Dr. Terry Baker Physician National Chest Hospital.

Fogarty International Center: HIV Research Training Program: New Applications and Strategies Gene D. Morse, PharmD University at Buffalo AIDS International.

Phyllis Kanki Harvard School of Public Health VIIIth Annual Track 1.0 ART Meeting August 2010.

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.

TB/HIV Research Approaches and Challenges Naomi Bock, MD Global AIDS Program Centers for Disease Control and Prevention February 14, 2005.

Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples.

HIV/AIDS IN PERU. Map General statistics Population million Life expectancy: Male: years Female: 75.6 years GNI billion Literacy.

Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.

Scaling up HIV Paediatric care Harvard – PEPFAR Program Chalamilla Guerino

AIDS Prevention Initiative Nigeria AIDS Prevention Initiative in Nigeria (APIN): Development and Status Prosper Okonkwo. MD APIN, Nigeria 8 th Annual Track.

Antiretroviral Pharmacovigilance Training Course Dar es Salaam, United Republic of Tanzania 23 rd – 28 th November 2009.

PEPFAR Investment Strategy (8 years of PEPFAR) Data source : OGAC Budget Total PEPFAR Investment: $21,285,918,291 Saving Lives : Changing the.

Involving National Coordinating, Regulatory and Ethical Bodies in HIV Vaccine Preparedness in Nigeria; The Canadian-Nigerian Collaboration Experience Evaezi.

Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modeling approach Dawn K.

Grant Presentation: Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme Linda-Gail Bekker, South.

Integration of HIV/AIDS and Cervical Cancer Programs for Improved Health Outcomes in Tanzania Dr. January Zilabumba IMA World Health 30 November, 2015.

Mövenpick Royal Palm Hotel Dar es Salaam, Tanzania August 4-6, 2009 The 7th Annual Track 1.0 ART Program Meeting.

Scaling-up HIV Prevention, Care and Antiretroviral Therapy at Primary Health Centers A WHO/PEPFAR Collaboration.

Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.

Implementing operational research for HIV treatment scale-up in resource-limited settings TB/HIV Research Priorities in Resource-Limited Settings Expert.

1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)

NIMR 6 th Annual Scientific Conference 10TH-12TH Nov. NIMR Auditorium, 6 Edmond Crescent, Yaba, Lagos. NIMR 6 th Annual Scientific Conference 10TH-12TH.

Adesina OA*, Awolude O, Oladokun A, Roberts A, Adewole IF, Department of Obstetrics & Gynaecology, College of Medicine, University of Ibadan. *Corresponding.

Harvard PEPFAR BotswanaNigeriaTanzaniaTotal Persons enrolled in HIV Care 18,687* 91,87571, ,487* Persons initiated on ART 13,275* 118,295 61,69644,404129,375*

Evaluation of Tuberculosis Drug Resistance among Nigerian HIV+ Patients in the Harvard PEPFAR/APIN Plus Program Using the Genotype MTBDRplus Test Lana.

Prevention of Mother-to-Child Transmission of HIV: Scale-up of Critical Services in Uganda (District- based Approach) Edward Bitarakwate, MD, MPH Technical.

1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)

1 Innovative rapid scale-up of effective PMTCT services to achieve virtual elimination of new pediatric HIV infections: A Zimbabwe experience Dr. Agnes.

Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:

1 NAME: TITLE:DATE:. 2 “One stop shop” for TB and HIV services improved initiation of antiretroviral therapy (ART) for co-infected patients in Eastern.

Hepatitis C Consultation Services (844) | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical.

Driving Future Success with Current Investments in HIV Research

NOVEMBER 15, 2017 PHILADELPHIA, PA

Friday, 1st October pm – 2.00pm

INTERNATIONAL AIDS SOCIETY Stakeholder consultation to address issues related to tenofovir prophylactic research SUMMARY MEETING UPDATE, MAY 2005, SEATTLE,

"3 by 5" progress December 2005.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Tuberculosis and the President’s Emergency Plan for AIDS Relief

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

Health Equity Strategic Meeting

Presentation transcript:

AIDS International Training & Research Program (AITRP) Research Workshop Abuja, Nigeria Rockview Hotel Royale (Ameachi Hall) May 6, 2010 FINAL Agenda Sponsored by: Northwestern University AITRP Harvard AITRP, Harvard PEPFAR, APIN

Thursday, May 6 th 8:30 – 9:00 AMRegistration 9:00 – 9:15 AMWelcome and Opening Comments (5 min)AITRP: Robert Murphy NACA: John Idoko CDC: Nancy Knight (10 min) NU AITRP Accomplishments to Date and Future Plans Baiba Berzins

9:15 – 10:45 AM NU AITRP Trainee Research: Projects and Goals (15 min)High-risk HPV DNA Testing and Detection of Cervical Squamous Intraepithelial Lesions Among HIV-positive Women with Normal Cytology Jonah Musa (15 min)Predictors of Second-line Antiretroviral Treatment Outcome in Ibadan Adedotun Adetunji (via audiorecording) (15 min)Evaluation of Concomitant Administration of Antimalarial Drugs on the Pharmacokinetics of Nevirapine in the Adult Nigerian Fatai Fehintola (15 min)Etravirine Phenotypic and Genotypic Susceptibility in HIV-1 Subtype Non-B After Failure of the First Generation NNRTI in Bamako, Mali Almoustapha Maiga (15 min)A prevalence study of MDR-TB in Ibadan, Nigeria: Exploring two rapid diagnostic assays Idowu Cadmus (10 min)TB Laboratory Training at SEREFO in Bamako, Mali Yetunde Fadairo (15 min) Opportunities in Clinical Microbiology Brehima Traore (via audiorecording) 10:45 – 11:00 AMTea Break

11:00 – 12:00 PM (15 min)Ethics in Research Jalal Hosseini (15 min)Knowledge and Practice of Research Incentives at JUTH: A Cross-sectional Study Samuel Odeh (15 min)Applied Biostatistics Training (Immersion Course, MS Epidemiology/Biostatistics) Adamu Onu 12:00 – 1:00 PMBuffet LUNCH 1:00 – 2:00 PM Research Opportunities: (20 min)Funding Opportunities at NIH, USAID, CDC & Foundations Robert Murphy (20 min)Grant Proposal Writing: Malignancies in HIV- International Training and Research Program (MHITRP) Chad Achenbach (20 min)Developing Global Health Collaborations Phyllis Kanki

2:00 – 4:00 PM (60 min) Research Priorities for Nigeria and Mali: Vision for the Future (10 min each)International: Rob Murphy NU AITRP – Clinical trials, ARVs: Babafemi Taiwo JUTH – Co-infections and Malignancies: Oche Agbaji UCH/Mali - PMTCT: Isaac Adewole, Mariam Sylla TB/HIV – Oni Idigbe (60 min) Opportunities for AITRP and PEPFAR Collaboration Moderators: Rob Murphy, Babafemi Taiwo Panel: Phyllis Kanki, Isaac Adewole, John Idoko, Prosper Okonkwo, Ernest Ekong, Manhattan Charurat